← All Merus NV filings

Merus NV DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

MRUS
Merus NV
DEFM14A: Genmab Offers $97/Share to Acquire Merus N.V.
Genmab A/S, through its subsidiary, has launched a tender offer to acquire all outstanding common shares of Merus N.V. for $97.00 per share in cash, with Merus's Board unanimously recommending the offer.
MRUS
Merus NV
DEFA14A: Merus N.V. to be Acquired by Genmab for $8 Billion Cash
Merus N.V. announced its agreement to be acquired by Genmab for approximately $8 billion in cash, or $97 per common share, representing a significant premium.
MRUS
Merus NV
DEFA14A: Merus to be Acquired by Genmab for $8 Billion Cash
Merus N.V. announced an agreement to be acquired by Genmab A/S for approximately $8 billion in cash, or $97 per common share.
MRUS
Merus NV
DEFA14A: Genmab to Acquire Merus for $8 Billion, Boosting Oncology Pipeline
Genmab A/S announced its intent to acquire Merus N.V. for $97.00 per share in an all-cash transaction valued at approximately $8.0 billion, aiming to expand its late-stage oncology pipeline.
MRUS
Merus NV
DEF: Merus N.V. Sets Date for 2025 Annual General Meeting, Outlines Key Proposals
Merus N.V. announces its 2025 Annual General Meeting of Shareholders to be held on May 21, 2025, featuring proposals including the adoption of annual accounts, auditor appointment, director re-appointments, and executive compensation approval.
MRUS
Merus NV
DEFA14A: Merus N.V. Updates Director Biographies Ahead of Annual General Meeting
Merus N.V. files a proxy supplement to update the biographical information of two directors, Sven (Bill) Ante Lundberg and Mark Iwicki, ahead of its Annual General Meeting on May 7, 2024.
MRUS
Merus NV
DEF 14A: Merus N.V. Seeks Shareholder Approval for Key Proposals at Upcoming Annual General Meeting
Merus N.V. is holding its Annual General Meeting on May 7, 2024, seeking shareholder approval on proposals ranging from financial statement adoption to director appointments and amendments to compensation plans.